Fifth Third Bancorp Purchases 2,485 Shares of Eli Lilly and Company $LLY

Fifth Third Bancorp increased its stake in Eli Lilly and Company (NYSE:LLY) by 0.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 466,067 shares of the company’s stock after acquiring an additional 2,485 shares during the period. Eli Lilly and Company comprises about 1.6% of Fifth Third Bancorp’s holdings, making the stock its 11th largest holding. Fifth Third Bancorp’s holdings in Eli Lilly and Company were worth $500,873,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Danske Bank A S grew its position in Eli Lilly and Company by 4.8% during the 4th quarter. Danske Bank A S now owns 703,564 shares of the company’s stock worth $756,106,000 after acquiring an additional 32,500 shares during the last quarter. Uptick Partners LLC grew its position in Eli Lilly and Company by 13.4% during the 4th quarter. Uptick Partners LLC now owns 678 shares of the company’s stock worth $729,000 after acquiring an additional 80 shares during the last quarter. Vantage Point Financial LLC grew its position in Eli Lilly and Company by 13.9% during the 4th quarter. Vantage Point Financial LLC now owns 1,214 shares of the company’s stock worth $1,305,000 after acquiring an additional 148 shares during the last quarter. Pegasus Asset Management Inc. grew its position in Eli Lilly and Company by 1.0% during the 4th quarter. Pegasus Asset Management Inc. now owns 9,274 shares of the company’s stock worth $9,967,000 after acquiring an additional 91 shares during the last quarter. Finally, GenTrust LLC grew its position in Eli Lilly and Company by 3.9% during the 4th quarter. GenTrust LLC now owns 777 shares of the company’s stock worth $835,000 after acquiring an additional 29 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 outperformance and raised guidance — Lilly reported a blowout quarter (revenue +55% YoY, EPS well ahead of estimates) and lifted full?year guidance, supporting the bull case for continued GLP?1 growth. LLY Q1 Deep Dive
• Positive Sentiment: Mounjaro dominance — Reports highlight Lilly capturing roughly 60% of the GLP?1 market and Mounjaro revenue surging, reinforcing market share and pricing power in obesity/diabetes treatments. Eli Lilly Captures 60% of the GLP?1 Market
• Positive Sentiment: Wall Street backing — Multiple firms boosted targets and ratings (Barclays to $1,400; Wolfe reaffirmed outperform with $1,325 target; Cantor Fitzgerald and others raised views), which can sustain buying pressure. Barclays Adjusts Eli Lilly Price Target
• Positive Sentiment: Shareholder returns — Board declared a $1.73 quarterly dividend, adding incremental income support for investors. Lilly Declares Second?Quarter 2026 Dividend
• Neutral Sentiment: Valuation/conviction pieces — Several outlets argue the pullback has made LLY’s valuation more attractive (Fool, 24/7 Wall St.), offering differing price targets and buy arguments for long?term investors. Is Eli Lilly Stock Heading for $1,000?
• Positive Sentiment: High?profile endorsements — Media/hosts (including Jim Cramer) have publicly praised Lilly’s weight?loss franchise and Foundayo, which can attract retail/institutional interest. Eli Lilly’s Weight Loss Pill is Better Than Novo’s, Says Jim Cramer
• Negative Sentiment: Foundayo safety signal — FDA records of liver?failure cases tied to Foundayo prompted a near?term selloff and caution from some investors; analysts largely view the reports as isolated but the item increases regulatory & PR risk. FDA Reports Liver Failure in Patient Taking Lilly’s Foundayo

Analyst Ratings Changes

Several equities analysts recently issued reports on LLY shares. Cantor Fitzgerald raised their price target on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a research report on Friday. Royal Bank Of Canada started coverage on Eli Lilly and Company in a research report on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 price target on the stock. Rothschild & Co Redburn raised their price target on Eli Lilly and Company from $875.00 to $880.00 and gave the stock a “neutral” rating in a research report on Friday, April 10th. The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,217.59.

Eli Lilly and Company Trading Up 0.4%

NYSE LLY opened at $967.49 on Tuesday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The firm has a market capitalization of $914.11 billion, a PE ratio of 34.37, a P/E/G ratio of 1.13 and a beta of 0.48. The stock’s 50 day moving average is $947.05 and its 200 day moving average is $987.36.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period in the previous year, the company posted $3.34 earnings per share. The firm’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts forecast that Eli Lilly and Company will post 33.79 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.